Geron (GERN) Earnings Date & Reports

Key Takeaways

• Geron reported third-quarter 2026 net product revenue of $60.1 million, up 27% year over year from $47.2 million and 5% sequentially.
• The company swung to a net profit of $1.4 million, or $0.00 per share, versus a net loss of $18.4 million ($0.03 per share) a year earlier.
• Management reiterated full-year 2026 Rytelo net revenue guidance at the mid-to-high end of the $220 million to $240 million range.
• Total operating expense guidance was lowered to $220 million to $230 million, down from a prior $230 million to $240 million.
• Geron discontinued the Phase 3 IMpactMF trial in myelofibrosis after an independent data monitoring committee determined it was unlikely to meet its primary endpoint.
• For deeper coverage of this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• You can also discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Geron Corporation (NASDAQ: GERN) is a commercial-stage biopharmaceutical company focused on hematology and oncology, with Rytelo (imetelstat) as its sole marketed product. Rytelo is a first-in-class telomerase inhibitor approved to treat adults with lower-risk myelodysplastic syndromes (MDS), a group of blood disorders, who have transfusion-dependent anemia. Because the company's entire commercial story currently hinges on Rytelo's U.S. launch trajectory, each quarterly report serves as a direct read on product adoption, pricing, and progress toward profitability. This quarter was especially significant because it marked Geron's transition into profitability while also revealing a pipeline setback in myelofibrosis, a decision that narrows near-term growth optionality and sharpens investor focus on Rytelo alone.

Reported Results

For the three months ended September 30, 2026, Geron reported total net product revenue of $60.1 million, a 27% increase from $47.2 million in the prior-year period and a 5% rise from the second quarter of 2026. Total revenue, including royalties, reached $60.19 million compared with $47.23 million a year earlier. On the bottom line, the company posted net income of $1.4 million, or $0.00 per share, a sharp reversal from the $18.4 million net loss ($0.03 per share) recorded in the same period last year.

Earnings per share (EPS) came in ahead of consensus, which had anticipated a loss of about $0.01 per share, while revenue of $60.1 million was roughly in line with the roughly $60.7 million analysts had modeled. The profit was driven by higher Rytelo sales and disciplined cost control: research and development (R&D) expenses fell to $12.7 million from $21.1 million, and selling, general and administrative (SG&A) expenses declined to $35.7 million from $39.0 million. Cost of goods sold (COGS) rose to $6.1 million from $1.0 million. Geron ended the quarter with approximately $339.4 million in cash, cash equivalents, restricted cash, and marketable securities.

AI Screener

Investors looking to apply the same rigor to broader market opportunities can use Tickeron's AI Screener, an AI-powered stock and exchange-traded fund (ETF) discovery tool. The screener helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The tool is designed to surface trade ideas, trending stocks, breakout candidates, and emerging opportunities far more efficiently than manual screening. For those monitoring companies like Geron, it offers a practical way to identify comparable setups across the biotechnology sector.

Market Reaction and Investor Sentiment

Geron shares rose sharply following the announcement, with the stock gaining roughly 16% in the trading session as investors responded to the company's first quarterly profit and continued Rytelo momentum. The market appeared to reward the combination of revenue growth, expense discipline, and improved guidance visibility, even as the discontinuation of the IMpactMF myelofibrosis trial removed a potential pipeline catalyst. Sentiment remains cautiously constructive, reflecting confidence in the Rytelo franchise tempered by recognition that Geron is now highly dependent on a single commercial asset and an early-stage European expansion strategy.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central theme for Geron is whether Rytelo can sustain its quarter-over-quarter growth in the U.S. while the company executes a capital-efficient international rollout. Management reiterated that full-year 2026 net revenue should land at the mid-to-high end of the $220 million to $240 million range, implying continued sequential expansion through the fourth quarter.

The European launch is a key near-term catalyst. Geron has initiated a gated commercial launch in targeted markets, beginning with Germany, where Rytelo is expected to be commercially available by the end of 2026, with France to follow in 2027. This hybrid model preserves pricing control while limiting upfront investment, but reimbursement and uptake dynamics will require close monitoring.

Investors should also track the fallout from the IMpactMF trial discontinuation. Management has committed to unblinding and analyzing the data, with findings potentially shared at future medical meetings, but the decision removes a meaningful diversification pathway. With Rytelo as the sole revenue driver, attention will turn to business development opportunities, cash deployment, and whether the company can translate its $339 million balance sheet into additional assets. Margin trends, gross-to-net deductions, and operating expense discipline will remain important indicators of the path toward sustained profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations